About this trial
This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing and DNA sequencing.
Eligibility criteria
Qualifiers
Patients aged 18 and up with suspected/confirmed MDS cases referred to BM evaluation either for diagnosis or risk assessment due to cytopenia
Platelets < 150 × 10E9/L or
Absolute neutrophil count < 1.8 × 10E9/L or
Hemoglobin (Hgb) < 13 g/dL (males) and < 12 g/dL (female) and
Disqualifiers
Women who are pregnant
Previous diagnosis of leukemia; AML, MPN, ALL, CLL, MGUS/MM or any other gammopathy
Lymphocytes > 5000/ul
Patients who are on disease-related therapy are excluded, unless they are treated with Erythropoietin or Prednisone. See Appendix 2 for the list of excluded treatments.
Trial design
Treatments tested in this trial
- PERIBLOOD-MDS